Edoceo Devices
Edoceo Devices is an emerging med-tech and biotech American company specializing in exclusive biosensor technology for rapid detection of viral and bacterial threats. Their mission is to develop portable, affordable, and accurate testing devices to provide early warning of pathogens, potentially saving lives and reducing economic impact. They focus on viral and bacterial diagnostics, including COVID-19, with products like A-Detect™, B-Detect™, and V-Detect™. The company's vision is to create a safer world through innovative sensors for life, addressing urgent health challenges with cutting-edge technology.
Industries
Nr. of Employees
small (1-50)
Edoceo Devices
Products
Saliva-based rapid antigen test (CE-marked)
A saliva-based rapid antigen test providing point-of-need results in 17 minutes or less; approved for sale in CE-marked markets and offered for distribution under a strategic agreement.
Portable bacterial testing device (prototype for virulent-state detection)
A portable device under development intended to detect approximately 160 bacterial species in a virulent (harmful) state with an objective of very rapid time-to-result (target <5 minutes); target markets include aquaculture, veterinary, food processing, healthcare and home monitoring.
Portable viral biosensing device (RNA amplification-based platform)
A portable viral biosensing platform designed to perform direct RNA amplification for the detection of viral targets with a simple readout; described for potential application across multiple viral pathogens.
Saliva-based rapid antigen test (CE-marked)
A saliva-based rapid antigen test providing point-of-need results in 17 minutes or less; approved for sale in CE-marked markets and offered for distribution under a strategic agreement.
Portable bacterial testing device (prototype for virulent-state detection)
A portable device under development intended to detect approximately 160 bacterial species in a virulent (harmful) state with an objective of very rapid time-to-result (target <5 minutes); target markets include aquaculture, veterinary, food processing, healthcare and home monitoring.
Portable viral biosensing device (RNA amplification-based platform)
A portable viral biosensing platform designed to perform direct RNA amplification for the detection of viral targets with a simple readout; described for potential application across multiple viral pathogens.
Services
Licensing of university-developed diagnostic platform and collaborative product engineering with university researchers to advance commercialization.
Distribution and sales of CE-marked saliva-based rapid antigen test through strategic agreements and agent networks in CE-requiring countries.
Licensing of university-developed diagnostic platform and collaborative product engineering with university researchers to advance commercialization.
Distribution and sales of CE-marked saliva-based rapid antigen test through strategic agreements and agent networks in CE-requiring countries.
Expertise Areas
- Point-of-need diagnostics
- Molecular diagnostics (RNA amplification)
- Lateral-flow assay development
- Bacterial virulence detection and rapid pathogen screening
Key Technologies
- Lateral-flow paper-based assays
- RNA amplification (portable molecular amplification)
- Microfluidic mixing and passive pumping
- Optical waveguide and label-free optical biosensing
News & Updates
Edoceo Devices announced a worldwide distribution agreement for a rapid saliva-based COVID-19 antigen test, A-Detect™, providing results in 17 minutes or less, approved in Europe, with plans for US FDA approval.
Edoceo licensed technology from Colorado State University to develop a portable, highly accurate COVID-19 test, aiming for market release within 12 months.
A report forecasts drug-resistant infections could kill more people than cancer by 2050, emphasizing the importance of rapid detection technologies.
A UK-backed report predicts antimicrobial resistance could cause 10 million deaths annually by 2050, costing the world $100 trillion.
Edoceo Devices signs a distribution deal for a rapid COVID-19 saliva test, approved in Europe, with plans for US approval.
Edoceo Devices announced a worldwide distribution agreement for a rapid saliva-based COVID-19 antigen test, A-Detect™, providing results in 17 minutes or less, approved in Europe, with plans for US FDA approval.
Edoceo licensed technology from Colorado State University to develop a portable, highly accurate COVID-19 test, aiming for market release within 12 months.
A report forecasts drug-resistant infections could kill more people than cancer by 2050, emphasizing the importance of rapid detection technologies.
A UK-backed report predicts antimicrobial resistance could cause 10 million deaths annually by 2050, costing the world $100 trillion.
Edoceo Devices signs a distribution deal for a rapid COVID-19 saliva test, approved in Europe, with plans for US approval.